We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.2B
AUM Growth
-$978M
Cap. Flow
-$700M
Cap. Flow %
-13.47%
Top 10 Hldgs %
44.11%
Holding
176
New
13
Increased
49
Reduced
69
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.9M
2
BRKR icon
Bruker
BRKR
+$21.3M
3
AMGN icon
Amgen
AMGN
+$19M
4
EHC icon
Encompass Health
EHC
+$16.6M
5
THC icon
Tenet Healthcare
THC
+$15.6M

Top Sells

Rank Stock Value
1
OPCH icon
Option Care Health
OPCH
+$51.8M
2
EPIX
ESSA Pharma
EPIX
+$47.8M
3
EXAS
Exact Sciences
EXAS
+$47M
4
CDNA icon
CareDx
CDNA
+$43.1M
5
EXEL icon
Exelixis
EXEL
+$41.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
2 Industrials 0.04%
3 Communication Services 0.03%
4 Technology 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
51
Merck
MRK
$313B
$26.3M 0.51%
264,226
+221,993
+526% +$22.9M
SAGE
52
DELISTED
Sage Therapeutics
SAGE
$24.2M 0.47%
4,460,693
– –
MOH icon
53
Molina Healthcare
MOH
$11.9B
$23.9M 0.46%
82,151
+14,589
+22% +$4.51M
AMGN icon
54
Amgen
AMGN
$198B
$23.3M 0.45%
89,240
+64,088
+255% +$19M
NTRA icon
55
Natera
NTRA
$37.8B
$23.1M 0.44%
145,676
+7,217
+5% +$1.05M
STE icon
56
Steris
STE
$21B
$22.6M 0.43%
109,887
+18,605
+20% +$4.08M
REGN icon
57
Regeneron Pharmaceuticals
REGN
$70.7B
$22.4M 0.43%
31,412
+4,636
+17% +$3.89M
ESPR
58
DELISTED
Esperion Therapeutics
ESPR
$21.9M 0.42%
9,944,064
– –
BMRN icon
59
BioMarin Pharmaceuticals
BMRN
$11.5B
$21.6M 0.42%
329,021
-1,955
-0.6% -$131K
BRKR icon
60
Bruker
BRKR
$8.62B
$21.1M 0.41%
+359,588
New +$21.3M
SRPT icon
61
Sarepta Therapeutics
SRPT
$1.81B
$20.8M 0.4%
171,317
-173,031
-50% -$21.2M
CSTL icon
62
Castle Biosciences
CSTL
$723M
$19.9M 0.38%
745,982
-516,048
-41% -$15.7M
PRVA icon
63
Privia Health
PRVA
$3.34B
$18.6M 0.36%
953,164
-106,007
-10% -$2.1M
HCA icon
64
HCA Healthcare
HCA
$82.1B
$18.6M 0.36%
61,883
-52,642
-46% -$18.4M
BDTX icon
65
Black Diamond Therapeutics
BDTX
$101M
$18.2M 0.35%
8,517,839
– –
HOLX
66
DELISTED
Hologic
HOLX
$17.9M 0.34%
247,886
+22
+0% +$1.72K
INSM icon
67
Insmed
INSM
$23.4B
$17.8M 0.34%
258,483
-266,951
-51% -$19.2M
COR icon
68
Cencora
COR
$59.3B
$17.4M 0.34%
77,522
+5,469
+8% +$1.29M
EHC icon
69
Encompass Health
EHC
$11.1B
$17.4M 0.34%
188,522
+169,289
+880% +$16.6M
NEO icon
70
NeoGenomics
NEO
$1.85B
$17.4M 0.33%
1,055,796
-556,816
-35% -$8.65M
ELV icon
71
Elevance Health
ELV
$82.7B
$14.1M 0.27%
38,343
-50,985
-57% -$21.3M
THC icon
72
Tenet Healthcare
THC
$16.7B
$13.9M 0.27%
110,230
+104,605
+1,860% +$15.6M
GPCR icon
73
Structure Therapeutics
GPCR
$3.34B
$13.2M 0.25%
485,050
-144,708
-23% -$5.13M
EVH icon
74
Evolent Health
EVH
$641M
$12.5M 0.24%
1,113,658
-1,556,392
-58% -$27.4M
SIBN icon
75
SI-BONE Inc
SIBN
$763M
$12.4M 0.24%
880,979
-563,130
-39% -$7.58M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2024 Portfolio in Review

As of Q4 2024, Bellevue Group held 176 positions worth $5.2B, down 16% from $6.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Bellevue Group withdrew a net $700M in Q4 2024, closing 15 positions and reducing 69 holdings. Its most notable exit was Option Care Health, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Bruker worth $21.1M.

  • Bellevue Group's largest Q4 2024 buy was Bruker: 359,588 shares worth $21.1M.
  • Bellevue Group added most to Merck in Q4 2024, an estimated $22.9M increase.
  • Bellevue Group's biggest Q4 2024 reduction was Exact Sciences, cutting an estimated $47M.
  • Bellevue Group fully exited Option Care Health in Q4 2024, selling an estimated $51.8M.
  • Bellevue Group's ten largest holdings make up 44% of its $5.2B portfolio in Q4 2024.
  • Bellevue Group opened 13 new positions and closed 15 in Q4 2024.
  • Bellevue Group's portfolio value fell 16% quarter-over-quarter to $5.2B.

Based on Bellevue Group's 13F filing for Q4 2024, filed 14 Feb 2025.